Skip to navigation Skip to content

Clinical Trial: Evobrutinib in Relapsing MS

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To affect immune function
Number of Subjects: 10
Medication: Evobrutinib vs. Teriflunomide
Location: Connecticut|New York
Institutions:  New England Institute for Clinical Research
30 Buxton Farm Road, Suite 230
Stamford, CT 06905 Contact Information
Megan Mulberry, ext. 125
203-914-1903
megan@neinh.com

Funding:

EMD Serono

Description

The purpose of this study is to characterize the efficacy and safety of evobrutinib 45 mg
administered orally twice daily versus teriflunomide (Aubagio®; 14 mg once a day orally) in
participants with relapsing multiple sclerosis (RMS).
 

Share


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.